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Abstract
The calcium-sensing receptor (CaR) is responsible for the regulation of extracellular calcium (Ca2+o) homeostasis.
CaR activation has been shown to increase proliferation in several cancer cell lines; however, its presence or func-
tion has never been documented in lung cancer. We report that Ca2+o-activated CaR results in MAPK-mediated
stimulation of parathyroid hormone–related protein (PTHrP) production in human lung squamous cell carcinoma
(SCC) lines and humoral hypercalcemia of malignancy (HHM) in vivo. Furthermore, a single nucleotide polymor-
phism in CaR identified from a hypercalcemia-inducing lung SCC reduced the receptor’s activation threshold lead-
ing to increased PTHrP expression and secretion. Increasing the expression of either wild-type CaR or a CaR variant
with a single nucleotide polymorphism in the cytoplasmic domain was both necessary and sufficient for lung SCC
to induce HHM. Because lung cancer patients who frequently develop HHM and PTHrP expression in lung cancer
has been only partially explained, the significance of our findings indicates that CaR variants may provide a positive
feedback between PTHrP and calcium and result in the syndrome of HHM.
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Introduction
Development of hypercalcemia of malignancy (HHM) results from
dysregulated secretion of parathyroid hormone–related protein
(PTHrP) typically in patients with epithelia-derived cancers. Studies
from developed nations in the 1970s and 1980s, as well as recent
studies from newly industrialized countries, report that patients with
SCC of the lung have the highest frequency of HHM (ranging from
27% to 66%) compared with other tumor types [1]. Recently, we
have identified mechanisms that activate high levels of PTHrP gene
expression in human lung SCC lines that produce HHM in xeno-
graft models [2,3]. In a subset of SCC lines capable of producing
HHM, autocrine EGFR-signaling through the mitogen-activated
protein kinase (MAPK) pathway induced high levels of PTHrP gene
expression, whereas in other lung SCC lines, such gene activation
was dependent on extrinsic host-derived factors [3].
The calcium-sensing receptor (CaR) is a central regulator of extra-
cellular calcium (Ca2+o) homeostasis. The biochemical properties of
CaR place it in the superfamily of G-protein–coupled receptors
(GPCRs). The CaR is activated in response to certain extracellular stim-
uli such as Ca2+,Mg2+, and amino acids, which stimulate phospholipase
C (PLC) to produce diacylglycerol and inositol 1,4,5-trisphosphate
(IP3). IP3 stimulates Ca
2+ release from the endoplasmic reticulum
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and activates signal transduction pathways, such as mitogen-activated
protein kinase–extracellular signal–related kinases (MAPK-ERK) and
MAPK–cJun–N-terminal kinase (JNK), whereas diacylglycerol acti-
vates protein kinase C (PKC) [4]. Signaling by CaR is negatively reg-
ulated, in part, by PKC-mediated phosphorylation of a threonine in
the intracellular domain (Thr888) [5,6]. Phosphorylation of this PKC
site inhibits activation of PLC by CaR and, therefore, serves as a neg-
ative feedback system.
The CaR regulates calcium homeostasis by inhibiting parathyroid
hormone secretion from the parathyroid chief cells and activating
Ca2+ reabsorption from the kidney thick ascending limb. The CaR
is one of just a few GPCRs where genetic mutations have been linked
with disease. For example, homozygous inactivating mutations of
CaR are responsible for neonatal severe hyperparathyroidism, which
results in severe hypercalcemia due to marked hyperparathyroidism,
secondary skeletal demineralization, and subsequent pathological
fractures [7]. The CaR is expressed in tissues beyond those directly
involved in mineral homeostasis such as the brain, pancreas and lens
epithelium. One function of CaR (at a nonparathyroid site) is phys-
iological regulation of PTHrP secretion by breast tissue [8].
Disruptions in calcium-mediated signaling pathways are well-
established features in the genesis and progression of cancer [9]. The
disturbance of calcium regulation in many lung SCC patients suggests
that CaR activation may contribute to altered intracellular calcium
(Ca2+i) signaling in the tumor or its microenvironment. Recent work
has detected CaR expression in adult lungs [10]; however, it is un-
known if CaR is present in human lung cancer or if it contributes
to the regulation of PTHrP expression and secretion.
In this report, we detected the expression of CaR in three human
lung SCC lines. In addition, we documented that CaR regulated
PTHrP gene expression and secretion in vitro. By using a xenograft
lung SCC model of HHM with a knockdown of CaR, we showed
that CaR was required for the rapid development of HHM. Further-
more, we demonstrated the presence of CaR single nucleotide polymor-
phisms (SNPs) in two lung SCC lines, HEK293T cells and human
lung SCC samples. Finally, we established that overexpression of the
CaR SNP R990G interfered with PKC-mediated feedback of recep-
tor signaling and was sufficient to induce HHM in a normocalcemic
xenograft model of lung SCC.
Materials and Methods
Cell Culture
The human RWGT2 SCC cell line was obtained from Drs G.
Mundy and T. Guise (University of Texas Health Science Cen-
ter, San Antonio, TX, and Indiana University School of Medicine,
Indianapolis, IN). The human HARA SCC cell line was obtained
from Dr Haruo Iguchi (National Cancer Center Research Institute,
Tokyo, Japan). The human BEN cell line was obtained from Dr T.J.
Martin (Brisbane, Australia) and was originally established from a
hypercalcemic patient with an SCC of the bronchus [11]. Transformed
human embryonic kidney 293 cells No. CRL-11268 (293T/17) at
cell passage 12 were purchased from American Type Culture Collec-
tion (Manassas, VA). All cell lines were authenticated by the Johns
Hopkins Genetic Resources Core Facility on October 26, 2010.
Purified genomic DNA was submitted for STR analysis using
AmpF/STR Identifiler (Applied Biosystems, Carlsbad, CA). Cell
lines were maintained in high-glucose Dulbecco modified Eagle
medium (DMEM) with GlutaMax (Invitrogen, Carlsbad, CA), sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS) at
37°C and 5% CO2. Cells were passaged at 90% confluence. In vitro
experiments, with the exception of Ca2+i release studies, were per-
formed when RWGT2, HARA, BEN, and HEK293T cells were
∼80% to 90% confluent.
Human Lung Biospecimens
Human lung biospecimens were provided by the eastern, mid-
western, and western divisions of the Cooperative Human Tissue
Network. Other investigators may have received specimens from
the same subjects. The research project was approved by the institu-
tional review board of The Ohio State University. Tissue specimens
were registered in their respective biobanks and kept anonymous.
Both nonaffected lung (NAT) and the primary lung squamous cell
tissues (SCC) were obtained for each patient sample (n = 40). No
patients had prior chemotherapy or radiation treatment. The bio-
specimens were diagnosed as lung SCC and staged by histopatho-
logic analysis.
Generation of shRNA-CaR, BEN, RWGT2, and
HARA Cell Lines
Briefly, 5 × 104 BEN, RWGT2, and HARA cells were seeded in a
12-well culture plate. Cells were transduced with SMARTvector
short hairpin RNA (shRNA) Lentiviral Particles, SMARTvector
Empty-Vector Control Particles or SMARTvector 2.0 Non-Targeting
Control Particles (Thermo Fisher Scientific, Lafayette, CO) at an
MOI of 40. Lentiviral particles used were as follows: a set of three
different shRNA constructs targeting CaR, GAPDH, an empty-
vector expressing TurboGFP, or a nontargeting negative control vector
(scrambled CaR sequence) expressing TubroGFP. Seventy-two hours
after initial transduction, gene knockdown was assessed by reverse
transcription–polymerase chain reaction (RT-PCR) of total cellular
complementary DNA (cDNA) and real-time confocal microscopy. Se-
lection for the maximally silenced shRNA-CaR cells in all three lung
SCC lines was achieved by FACS analysis from which a 1 × 104 pop-
ulation of cells with the greatest fluorescent reporter function were
selected for use in additional studies.
Real-time Confocal Laser scanning Microscopy for
Determination of Ca2+i
Determination of Ca2+o-induced changes in Ca
2+
i was done by
loading the lung SCC lines with Ca2+-sensitive fluorescence probes,
fluo-3AM, or rhod-2AM for GFP-expressing cell lines (Molecular
Probes, Carlsbad, CA). Ca2+i dynamics in single cells was measured
as previously published [12].
PTHrP Analysis
PTHrP (1-86) concentrations in plasma and cell culture–conditioned
media were measured using a commercially available two-site immuno-
radiometric assay (Diagnostic Systems Laboratories, Houston, TX).
Xenografts in Nude ( Foxn1nu) Mice and Biochemical Analysis
All experimental procedures were approved by The Ohio State
University Institutional Laboratory Animal Care and Use Com-
mittee. Tumors were grown, and hypercalcemia was monitored as
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described [3]. Plasma and total calcium concentrations ([Ca2+]) were
measured using the Vitros DT-60 II clinical chemistry analyzer
( Johnson & Johnson, Ramsey, MN). Animals were considered hyper-
calcemic when total plasma [Ca2+] were ≥12 mg/dl.
Statistics
Results were expressed as the mean ± SEM of triplicate or quadru-
plicate measurements with the exception of the PTHrP secretions
studies in which the results were expressed as mean ± SD and com-
pared with the two-tailed Student’s t test. A probability value of P <
.05 was considered to be significant. Analyses of variance (ANOVAs)
were used to analyze the time differences between groups. If the
equal-variance test failed when comparing multiple groups, a Kruskal-
Wallis one-way ANOVA on ranks followed by the Dunn method of
multiple comparison was used to analyze differences in tumor volume
and [Ca2+]. Plots with the variable time in the x axis are reported to
show the trends over time (SigmaPlot 11, Chicago, IL).
Results
CaR mRNA and Protein Were Expressed in Human Lung
SCC Lines
RT-PCR and Western blots were used to detect CaR mRNA and
protein in three lung SCCs (BEN and HARA derived from primary
pulmonary tumors and RWGT2 derived from a bone metastasis). All
lines have been reported to express moderate to high levels of PTHrP
[13–15], but only HARA and RWGT2 produce hypercalcemia in
mice. Structure-function relationships of CaR have been traditionally
studied using the putatively receptor-negative HEK293 cells. Posi-
tive controls for CaR expression included the receptor transfected
HEK293 line, kidney, as well as breast and prostate cancer lines [16].
The CaR product was amplified from the cDNA of all lung SCC lines
and surprisingly the HEK293T cell line (Figure 1A). An immunoreac-
tive band was detected at 130 kDa in HEK293T cells and all lung SCC
extracts on Western blots, similar to the mannose-modified intracellu-
lar form of CaR present in human whole kidney lysate (Figure 1B).
Figure 1. CaR mRNA and protein expression in lung SCC cells and the effect of [Ca2+]o on PTHrP secretion. (A) RT-PCR amplification of
CaR from HEK293T (HEK) (historical negative control for CaR expression) (lane 2), BEN, RWGT2 (RW), and HARA (HA) lines and positive
controls (+Cntrls) CaR-transfected HEK293T (HEK-CaR) (lower lane 2) human kidney tissue (KID), the PC-3 prostate carcinoma cells
(PC-3), and the breast cancer line, MDA-MB-231(MDA). Lane 1 is a ladder. CaR-specific human primers amplified a single 481-bp product
in all cell lines including HEK293T. (B) Relative CaR expression by Western blots of cell extracts from adult human kidney (KID)
(+ control) lane 1, HEK293T cells (HEK) from ATCC lane 2, and lung SCCs. Experiments were repeated three times and data from
a representative blot are shown. (C–E) PTHrP secretion after treatment with increasing [Ca2+] or spermine (2.0 mM). CaR activation
increased [PTHrP] at all time points with an ECmax of approximately 3.0 mM Ca
2+ excluding spermine treatments. Each value is the
mean ± SD of three experiments. *Significant difference between treatment and cells grown in 0.15 mM (*P < .05 vs 0.15 mM).
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Figure 2. Increasing [Ca2+]o induced a biphasic Ca
2+
i rise in lung SCC cells. (A–D) The graphs are representative of fluo-3 fluorescent Ca
2+
i
responses observed in typical experiments using each lung SCC line and HEK293T cells. Ca2+i baseline was measured in 0.0 mM Ca
2+
solution, and Ca2+i oscillations were initiated by the addition of 0.15 mM Ca
2+. The panels below are confocal microscopy images depict-
ing fluo-3–loaded cells at baseline (a) and subsequent emittance of fluorescence on stimulation with Ca2+o (b). Magnification, ×10.
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Treatment with Ca2+o Increased PTHrP mRNA Expression
and Secretion
Cell viability of the three lung SCCs lines was assessed after 24 hours
to increasing [Ca2+]o or spermine, a potent CaR activator. No sig-
nificant effect on cell viability of any of the lung SCCs was found
(Figure W1, B–D). Cells were treated with increasing [Ca2+]o and
2.0 mM spermine for PTHrP mRNA expression and protein secretion
studies. The concentrations of Ca2+o were selected to range from the
serum-ionized calcium of a normal patient, 4 mg/dl (1.0 mM) through
those equivalent to a patient with HHM, 12mg/dl (3.0 mM) and levels
toxic to normal human tissues 5.0 mM. Figure W2 shows that treat-
ment of all three lung SCC lines with 3.0 mM Ca2+ resulted in sta-
tistically significant increases in PTHrP/GAPDH mRNA ratios at all
but one time point. A significant stimulation of PTHrP secretion at
3.0 mM Ca2+ versus 0.15 mM was present in all cell lines at the ma-
jority of time points (Figure 1, C–E ). PTHrP secretion after treat-
ment with 3.0 mM Ca2+ was generally greater than with 5.0 mM.
These data demonstrated that PTHrP expression and secretion could
be increased by elevated Ca2+o levels.
Our data implicate CaR as a regulator of PTHrP secretion in lung
SCC. The frequency of Ca2+i oscillations has been linked to changes
in gene expression [17,18]; therefore, we hypothesized that stimula-
tion of CaR and the resulting Ca2+i release as represented by either
oscillation frequency or amplitude may account for the differences in
PTHrP expression. We used real-time confocal microscopy to mea-
sure Ca2+ released from intracellular stores. BEN cells exhibited a
gradual increase in Ca2+i (Figure 2A), whereas RWGT2 cells did
not respond until stimulation with 1.0 mM Ca2+o when an abrupt
increase in Ca2+i occurred (Figure 2B). The HARA cells displayed
vigorous concentration-dependent oscillations of Ca2+i with a maxi-
mum F /F0 ratio of approximately 2.5 when stimulated with 1.0 mM
Ca2+o (Figure 2C ). Importantly, when the HARA cells were treated
Figure 3. shRNA-CaR reduced CaR mRNA expression, PTHrP secretion, and Ca2+i release. (A) RT-PCR detection of CaR from SCC lines
transduced with lentiviral shRNA to CaR (Sh2), scrambled-control RNA (SC), empty-vector (EV), or nontransduced (NC). (B, D, F) The
graphs are representative of rhod-2 fluorescent Ca2+i responses from each shRNA-CaR line. The panels below Ca
2+
i response curves
labeled (a, b) are confocal microscopy images depicting rhod-2–loaded cells at baseline before stimulation (a) and after stimulation with
3.0 mM Ca2+o in the same cell (b) the third panel depicts GFP expression from the transduced vector. The shRNA-CaR lines had reduced
PTHrP secretion (C, E, and G). Reduction of PTHrP secretion was 31%, 55%, and 74% for BEN (Figure 1C vs Figure 3C), RWGT2
(Figure 1D vs Figure 3E), and HARA (Figure 1E vs Figure 3G), respectively.
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with just 0.5 mM Ca2+o, a two-fold increase in Ca
2+
i occurred, an
intensity that was greater than the fold increase achieved by either
the BEN or RWGT2 lines. The significantly greater intensity in fluo-
rescence acquired at a lower [Ca2+]o in HARA can be described as
shifted to the left when compared to other lines, suggesting a poten-
tial for differential signaling downstream from the receptor.
Inhibition of CaR Expression Reduced Ca2+i Mobilization and
PTHrP Gene Expression, Delaying the Onset of HHM
To further characterize the role of CaR in the SCC lines, we
knocked down endogenous CaR using a lentiviral short-hairpin in-
terfering RNA (shRNA-CaR) and examined gene expression for CaR
and its signaling (Figure 3A). Transduction of shRNA-CaR reduced
CaR in all lung SCC lines and markedly decreased Ca2+o-induced
Ca2+i responses (Figure 3, B, D, and F ). These data support the con-
clusion that Ca2+i oscillations are Ca
2+-dependent through the acti-
vation of CaR.
The results from the Ca2+o stimulation studies indicated that Ca
2+
o
may have activated PTHrP secretion in the lung SCC lines via the
CaR. PTHrP secretion in response to [Ca2+]o and spermine in the
shRNA-lung SCC CaR clones was measured and found to be reduced
in all three lines (Figure 3, C , E , and G ). These results definitively
demonstrated that CaR was necessary for lung SCC cells to secrete
high levels of PTHrP in response to elevated Ca2+o.
We investigated whether CaR was required for the development of
HHM in lung SCC by comparing the time to development of hy-
percalcemia between a xenograft mouse model of HARA carrying a
shRNA empty-vector clone and mice carrying the HARA shRNA-
CaR clone. The Kaplan-Meier long rank survival analysis revealed
a significant difference (P = .023) between the groups when hyper-
calcemia was identified (i.e., the time point represents the very first
day HHM was identified and therefore the date of euthanasia). The
HARA shRNA empty-vector line produced hypercalcemia in less
time after tumor cell injection than the HARA shRNA-CaR cells
(50% of the HARA shRNA empty-vector mice were hypercalcemic
in 29 days vs HARA shRNA-CaR in which 50% of the mice were
hypercalcemic in 49 days) as shown in Figure 4A. Moreover, there
were no differences found in tumor volume or weight (data not
shown) between the HARA shRNA empty-vector and HARA
shRNA-CaR groups (Figure 4B), which indicates that the increased
time to development of HHM was not due to altered growth of the
Figure 4. The CaR was necessary for the rapid development of HHM in the HARA xenograft model. (A) Kaplan-Meier analysis indicated
HHM developed more rapidly in HARA shRNA empty-vector mice than HARA shRNA-CaR (P = .023). (B) Average tumor volume at the
time of hypercalcemia. (C) Average plasma [PTHrP] in the HARA shRNA empty-vector mice were 190% greater (23 vs 8.0 pM) compared
to the HARA shRNA-CaR mice (P = .11). (D) Comparison of plasma total [Ca2+] in HARA shRNA empty-vector and HARA shRNA-CaR
mice before xenografting (baseline) and at the time of HHM. No differences were observed.
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shRNA-CaR tumors. The results suggested that CaR was necessary
for the rapid development of HHM in the HARA xenograft model.
Decreased Immunohistochemical Expression of CaR and
PTHrP in Lung SCC Xenograft Tumors from HARA
shRNA-CaR Mice
The immunoreactivity of CaR and PTHrP was investigated in xeno-
graft tumors derived from mice injected with either the HARA shRNA
empty-vector or the HARA shRNA-CaR clone. The phosphoCaR
antibody produced a specific and robust cytoplasmic and nuclear
signal (Figure W3, A and B), whereas the PTHrP antibody produced
a moderately intense diffuse, finely granular cytoplasmic, and sparse
nuclear pattern in lung SCCs from the HARA shRNA empty-vector
tumor (FigureW3, C andD). Both phosphoCaR- and PTHrP-positive
reactions were successfully blocked with their respective blocking
peptides. A significant decrease in staining intensity was evident for
both the phosphoCaR and PTHrP antibodies in the lung SCC tu-
mors from the HARA shRNA-CaR group. The phosphoCaR stain-
ing distribution was strikingly decreased in the cytoplasm and barely
detectable in the nucleus (Figure W3, E and F ). PTHrP antibody
staining remained primarily localized to the cytoplasm and was mark-
edly reduced (Figure W3, G and H ). The results of the immunohis-
tochemistry confirm that use of shRNA to silence CaR expression in
HARA lung SCCs decreases both CaR protein and downstream
PTHrP production. The specificities of the primary phosphoCAR
and PTHrP antibodies were further evaluated on normal human adult
lung tissue sections. In accordance with the work of Milara et al.
[10], the phosphoCaR antibody staining pattern showed detection of
CaR in a pulmonary artery and bronchi (Figure W3I ) in lung paren-
chyma and type 2 pneumocytes (Figure W3J ). Furthermore, PTHrP
was located on the endothelial venules, capillaries (Figure W3K ) and
in nuclei of type 2 pneumocytes (Figure W3L), exclusive locations in
which PTHrP has been detected previously in the adult lung [19,20].
Altered CaR Signaling in HARA Cells
Our findings of the dependence of PTHrP secretion on CaR and a
leftward-shifted Ca2+i mobilization response to Ca
2+
o suggested that
the HARA line may exhibit an overall gain-of-function downstream
Figure 5. Ca2+o induced CaR phosphorylation at threonine 888 and ERK1/2 phosphorylation. (A) Western blots of protein lysates from
5.0 mM Ca2+ treated BEN and HARA cells at various time points probed with CaRT888 phosphorylation-specific antibody. GAPDH West-
ern blot serves as a loading control. (B) Densitometry: the levels of phosphorylated CaR were normalized to total CaR and GAPDH.
Results were from three experiments. Bars, SEM. *BEN p-CaR/t-CaR: P < .05, compared to 0 time point. †HARA p-CaR/t-CaR: P <
.05, compared to 0 time point. §BEN p-CaR/t-CaR versus HARA p-CaR/t-CaR: P < .05. (C) Western blots of protein lysates from 3.0 mM
Ca2+–treated BEN and HARA cells at various time points probed with antibodies against ERK1/2 phosphorylation, total ERK, and GAPDH.
(D) Quantitative analysis by densitometry. The levels of phosphorylated ERK1/2 were normalized to total ERK and GAPDH as above. Bars,
SEM. *BEN p-ERK1/2/t-ERK: P < .05, compared to 0 time point. †HARA p-ERK1/2/t-ERK: P < .05, compared to 0 time point. §BEN p-ERK1/
2/t-ERK versus HARA p-ERK1/2/t-ERK: P < .05.
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of receptor signaling. Therefore, we examined CaR phosphorylation
and the activation of downstream signal transduction pathways in
the HARA line and the less Ca2+o-responsive BEN line. Regulation
of PKC negative feedback induced by CaRT888 phosphorylation
was examined in cell lysates from BEN and HARA cells at multiple
time points using a custom-made polyclonal antibody raised to this
epitope. Treatment of the HARA cells with 5.0 mM Ca2+ resulted in
maximum CaRT888 phosphorylation at 60 minutes, whereas the
maximum in the BEN cell line occurred at 5 minutes (Figure 5, A
and B). This finding suggested that the negative feedback in the
HARA CaR was delayed when compared to BEN.
To identify the molecular pathway involved in coupling PKC
activation to CaR-activated PTHrP secretion, we used a human
phosphoMAPK array to assess the relative level of phosphorylation
of MAPKs in the BEN, HARA, and shRNA-CaR lines. The phospho-
MAPK array detected strong phosphorylation of ERK1 (MAPK3),
ERK2 (MAPK1), and JNK2 in both cell lines in response to Ca2+
stimulation as well as a decrease in the phosphorylation of both
ERK1/2 in the companion shRNA-CaR lines (Figure W4, A and
B). Thus, both ERK and JNK are activated to different extents in
BEN and HARA lines.
We next examined the temporal activation of the ERK1/2, which
has been implicated in mediating CaR post–receptor signaling and
activation of PTHrP expression and secretion [21–23]. As shown
in Figure 5C , ERK1/2 phosphorylation was increased in the HARA
cell line at 5 minutes, whereas treatment of BEN required 10 min-
utes. ERK phosphorylation in the BEN cell line began to decrease at
15 minutes but persisted to 30 minutes in HARA. Thus, HARA
seems to have prolonged activation of the MAPK pathway relative
to BEN.
To further understand the basis of the altered CaR signaling in
the HARA line, sequencing of genomic DNA for each cell type was
performed. No mutations or SNPs were identified in the RWGT2
line. Interestingly, a homozygous missense SNP was identified in the
Figure 6. Ca2+o-stimulated Ca
2+
i release in RWGT2 or RWGT2 transduced with CaR
WT, CaRA986S, CaRQ1011E, or CaRR990G. (A–E) The
graphs are representative of rhod-2 fluorescent Ca2+i oscillations observed in RWGT2 and RWGT2 lines stably transduced with a
GFP-expressing construct for either CaR wild-type receptor (CaRWT) or the CaR mutations, CaRA986S, CaRQ1011E, or CaRR990G. Ca2+i
baseline was measured in 0.0 mM Ca2+ bathing solution, and Ca2+i oscillations were initiated by the addition of 0.15 mM Ca
2+. The
panels below the Ca2+i response curves labeled (a, b) are confocal microscopy images depicting rhod-2–loaded cells at baseline (a) and
subsequent emittance of fluorescence on stimulation with Ca2+o (b). The third panel in B to E depicts GFP expression from a GFP-CaR
fusion protein.
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HARA (R990G) and BEN (Q1011E) lung SCC line, as well as a
heterozygous SNP in HEK293T (A986S) cells (Figure W5A and
Table W2A). All of the identified SNPs were located in exon 7 that
encodes part of the cytoplasmic region of the receptor (Figure W5B).
To follow up the cell line findings, the CaR gene was sequenced from
nonaffected and affected lung tissues from 20 patients diagnosed
with lung SCC. Surprisingly, the specific SNPs observed in the cell
lines occurred in both the nonaffected and affected lung tissues in
6 (30%) of 20 patients (Table W2B). These findings raise the intrigu-
ing possibility that certain CaR SNPs may be associated with the
development of lung SCC.
Functional Assessment of CaR SNPs
To characterize the functional properties of the CaR SNPs, we
measured Ca2+i oscillations after stimulation with Ca
2+
o in RWGT2
cells transduced with lentiviral constructs containing the individual
CaR wild-type (WT) and SNPs A986S, R990G, and Q1011E. Cells
transduced with WT CaR had a threshold for a response to [Ca2+]o
between 3.0 and 5.0 mM, whereas this occurred between 1.0 and
3.0 mM in the nontransduced RWGT2. Overexpression of CaRWT
resulted in a two-fold increase and sustained release of Ca2+i at
5.0 mM Ca2+o (Figure 6, A and B). The overexpression and stim-
ulation of the CaRA986S in RWGT2 resulted in delayed Ca2+i re-
lease occurring at 5.0 mM and was the least robust compared to
the untransduced cell line (Figure 6, A vs C ). Ectopic expression of
CaRQ1011E in RWGT2 produced a threshold response to [Ca2+]o be-
tween 3.0 and 5.0 mM and also resulted in a more robust dose-
response curve than CaRWT. Overexpression of CaRR990G in RWGT2
led to a maximum Ca2+i release at 5.0 mM Ca
2+
o with a 3.8-fold in-
crease in fluorescence intensity, which represented the greatest Ca2+i
release (Figure 6E).
Because the in vitro functional assessment of the CaRR990G variant
suggested it had a gain-of-function in terms of activating signaling
in response to high [Ca2+]o, we tested whether CaR
R990G expressed
in a normocalcemic lung SCC model would induce a rapid onset
of HHM. The overexpression of CaRWT in the BEN line resulted
in the development of HHM, whereas the vector-transduced lines
did not (Figure 7A). A significant difference in time to onset of hyper-
calcemia was observed (P < .001) between BEN CaRR990G and BEN
CaRWT (36 vs 49 days). Moreover, there were no differences in the
mean tumor volume at the time of euthanasia. Average plasma PTHrP
concentrations in the BEN CaRR990G mice were 35% and 280%
greater compared to the BEN CaRWTand vector-transduced mice, re-
spectively (Figure 7C ). The results demonstrated that overexpression
of CaRWT was sufficient for the development of HHM in the BEN
xenograft model, and the expression of CaRR990G variant predisposed
to an earlier onset of HHM.
Discussion
We have shown that lung SCCs express the CaR and that stimulation
of CaR by Ca2+o results in downstream activation of the MAPK
pathway and up-regulation of PTHrP mRNA expression and secre-
tion. In addition, CaR variants have been identified that, when ec-
topically expressed, alter Ca2+i release. It seems that CaR is a critical
factor for the rapid development of HHM because either overexpres-
sion of wild-type or CaRR990G variant was sufficient to induce HHM
in a normocalcemic lung SCC xenograft model. Therefore, Ca2+o may
act as an important stimulus to activate CaR in some lung SCCs.
The identification of CaR expression in lung SCC lines suggests a
potential mechanism that contributes to abnormal calcium homeo-
stasis in patients with lung SCC. The activation of PTHrP was largely
abrogated in cells with shRNAs against CaR consistent with a role
for the receptor in HHM rather than an indiscriminate effect of
[Ca2+]o on plasma membrane ion channels known to impact gene ex-
pression. Intriguingly, PTHrP expression and secretion were greatest
at 3.0 mM Ca2+, whereas toxic concentrations of Ca2+ (5.0 mM) de-
creased mRNA and secreted protein levels. Data show that the ele-
vated serum Ca2+ concentrations as seen in HHM could stimulate
Figure 7. Xenograft models of BEN SCCs overexpressing either CaRWT, CaRR990G or the empty-vector. (A) Kaplan-Meier analysis indi-
cated HHM developed more rapidly in BEN CaRR990G than BEN CaRWT (P < .001). (B) Tumor volume at the time of hypercalcemia (P <
.05). (C) Comparison of plasma PTHrP in the mice with tumors. Mice with BEN CaR tumors were hypercalcemic, and mice expressing
BEN empty-vector cells were not. Plasma PTHrP was measured before xenografting (baseline), at the time of development of HHM for
the BEN CaR-bearing mice, and at the time of meeting early removal criteria for the BEN empty-vector xenografts.
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CaR and provide a positive feedback loop to further activate PTHrP
gene expression.
The use of shRNA to silence CaR expression permitted us to ex-
amine the role of the receptor in xenograft models of HHM. shRNA
to CaR decreased PTHrP expression in SCC lines and confirmed the
role of CaR in the activation of intracellular signaling, leading to in-
creased PTHrP production. However, shRNA for CaR in HARA
cells did not completely abrogate PTHrP expression or the ability
to induce hypercalcemia in vivo. This is likely due to other humoral
factors that contribute to PTHrP gene expression in vivo such as
TNF-α, IL-1, IL-6, and/or stroma-derived cytokines. Transactivation
of EGFR by CaR induction of membrane-associated matrix metallo-
proteinases, such as ADAM-17, has been reported in the HHM mice
with PC-3 and Leydig H-500 cell lines [24,25]; however, we did
not observe increased EGFR phosphorylation in HARA xenografts,
suggesting that this mechanism did not significantly contribute to
PTHrP production [3]. Alternatively, HHM may result from CaR
signaling through Gαq11 and PLC, which raises the possibility that
PTHrP secretion could be induced by activation of other GPCRs
that activate the ERK1/2 signaling pathway.
The identification of CaR SNPs in lung SCC demonstrates that
receptor variants can influence signaling in cancer cells consistent
with previous reports of receptor missense variants in endocrine dis-
eases. The three identified SNPs encode missense amino acid changes
(A986S, R990G, and Q1011E) in the C-terminus of CaR. Unfortu-
nately, patients’ serum calcium values at the time of diagnosis were
not available for the samples from which the CaR was sequenced. We
performed a functional analysis of the SNPs in a lung SCC line
that had WT CaR because a cell line lacking the receptor remains
to be identified. In our studies, RWGT2 cells transduced with the
CaRR990G SNP did not have an EC50 Ca
2+
i release consistent with
an activating mutation when compared to RWGT2 transduced with
CaRWT, although a greater release of Ca2+i occurred at 5.0 mM. This
suggested that variant receptor dimerization with the endogenous
wild-type partially negated the gain-of-function observed for a homo-
zygous R990G SNP in the HARA cell line. The R990G SNP of the
CaR has been associated with primary hypercalciuria in patients with
and without renal calculi [26,27]. Similar to our findings, Vezzoli
et al. [26,28] suggest the 990G allele resulted in a gain-of-function
of the CaR in HEK293 cells. Clinically, the presence of a hetero-
zygous R990G variant in a lung cancer patient confirmed to have
HHM would predict rapid progression of HHM once established,
whereas a patient with a homozygous R990G SNP would likely
develop HHM earlier because PTHrP production would be stimu-
lated when serum Ca2+ was within the normal physiologic range. Fi-
nally, interpretation of our findings has been complicated because all
published functional CaR studies have been performed in some de-
rivative of HEK293 cells. It is quite possible that the previous con-
clusions about mutant CaR function have been influenced by the
variants such as the A986S SNP present in the HEK293T cell line.
The role of CaR in disturbances of calcium homeostasis triggered by
lung SCCs has led us to speculate on the potential therapeutic strate-
gies directed at the receptor. Restoring normal CaR function may con-
tribute to lessening the sequelae of cancer, particularly HHM, and
could play a supporting role in cancer treatments. On the other hand,
negative allosteric modulators (calcilytics) of the CaR, which decrease
receptor activation, seem appealing for use in a patient with HHM. A
potential limitation may be the lack of specificity for tumor-associated
CaR, leading to unintended consequences such as stimulation of en-
dogenous PTH secretion and renal calcium reabsorption with a resul-
tant elevation or unchanged serum calcium concentration. In addition,
the role of CaR variants on the function of these drugs may be impor-
tant because mutations or SNPs may compromise allosteric binding
sites for the inhibitors.
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Supplemental Materials and Methods
Reagents
Spermine tetrahydrochloride was purchased from Sigma-Aldrich (St.
Louis, MO). Mouse antihuman CaR monoclonal to amino acids (AA)
15-29 of the extracellular N-terminus (Sigma-Aldrich) was used for
Western blot analysis. Adult normal human kidney whole-cell homoge-
nates, normal human kidney lysate, and the secondary rabbit anti-mouse
HRP antibody were purchased from Abcam, Inc. (San Francisco, CA).
Phosphorylation of CaR residue Thr888 was studied using a custom-
made rabbit polyclonal antibody to the phosphorylated form of
Thr888, which is within AA 882-896 of the human CaR sequence
(KVAARA(pT)LRRSNVSR) (Invitrogen) [5]. For additional immuno-
blot studies, the following antibodies were used at a dilution of 1:000:
anti–phospho-p44/42 MAP kinase (Thr202/Tyr204) no. 9101 and
anti–p44/42MAP kinase, GAPDH no. 2118 (Cell Signaling, Danvers,
MA); and anti–β-actin was used at 1:5000 dilution (Sigma-Aldrich).
MTT Assay
A colorimetric assay (CellTiter 96 Non-Radioactive Cell Prolifer-
ation Assay; Promega, Madison, WI) was used according to the man-
ufacturer’s instructions to measure cell number and/or viability.
Briefly, 5000 cells of each cell line were seeded in a 96-well culture
plate in 100 μl of normal growth media and were incubated at 37°C
in humidified 5% CO2 for 24 hours. The following day, normal
growth medium was replaced by 100 μl of CaCl2-free DMEM
supplemented with L-glutamine and 10% dialyzed FBS (0.15 mM
Ca2+). Calcium chloride was used as the active agent for [Ca2+]o de-
livery and was added to the calcium-free DMEM to give final total
calcium concentrations of 0.5, 1.0, 3.0, and 5.0 mM. The medium
supplemented with the polycationic CaR agonist, spermine (2 mM),
was used as a positive control. Twelve wells of each cell type were
used for each [Ca2+] and spermine treatment. Cells were incubated
with CaR agonist treatments at 37°C in humidified 5% CO2 for
24 hours.
RNA Isolation and Quantitative Real-time RT-PCR
Total RNAwas isolated from human lung tissue and lung SCC lines
using the Absolutely RNA Miniprep Kit (Stratagene, La Jolla, CA) ac-
cording to the manufacturer’s instructions. The quality and quantity of
the RNA were determined spectroscopically using a NanoVue Spectro-
photometer (GE Healthcare, Piscataway, NJ). TaqMan Reverse Tran-
scription kits (Applied Biosystems, Carlsbad, CA) were used to make
cDNA for quantitative real-time PCR (QRT-PCR) analysis of all tran-
scripts of PTHrP. The unlabeled primers and MGB FAM dye-labeled
probe set for PTHrP QRT-PCR was from a Pre-Developed TaqMan
Gene Expression Assay (Applied Biosystems). Absolute quantification
was performed by interpolating quantities of unknown sample from a
standard curve derived from known concentrations of PTHrP and
GAPDH dilutions. Data were normalized by use of the ratio of the
target cDNA concentration to GAPDH to correct for differences in
RNA quantity between samples. The results represented in the figures
were derived from experiments where the cDNAs were prepared at the
same time and then analyzed by QRT-PCR performed on one plate
when possible.
PTHrP Secretion Assays
For studying the effects of Ca2+o and the polycationic CaR agonist,
spermine, on PTHrP secretion, the three lung SCC lines and their
respective shRNA-CaR lines were seeded in triplicate at a density of
3 × 106 cells/100 mm in polystyrene tissue culture dishes (Falcon,
BD Biosciences, Bedford, MA) with 10 ml of normal growth me-
dium. After 48 hours, the medium was removed from each plate,
cells were washed with Dulbecco phosphate-buffered saline (DPBS),
and the medium was replaced with 10 ml of sodium pyruvate and
CaCl2-free high-glucose DMEM (Invitrogen) supplemented with
10% dialyzed triple 0.1-μm sterile-filtered FBS (HyClone, Logan,
UT) and 4 mM L-glutamine alone (0.15 mM) or supplemented with
CaCl2 to concentrations indicated in figures or 2 mM spermine.
Medium-ionized [Ca2+] was confirmed using a calcium analyzer (Stat
Profile Critical Care Xpress; Nova Biochemical, Waltham, MA). At
times indicated after the addition of Ca2+ or spermine, the condi-
tioned medium was removed and evaluated with two-site immuno-
radiometric assay (Diagnostic Systems Laboratories).
Immunoblot Analysis
For the measurement of CaR and actin proteins in lung SCC and
HEK293T cells, cells were grown to 90% confluence in 100-mm
dishes, subsequently placed on ice, rinsed with ice-cold DPBS, and
lysed with a cold solution containing 20 nMHEPES (pH 7.4), 20 mM
NaCl, 5 mM EDTA, 5 mM EGTA, 1 mM dithiothreitol, 0.5% Triton
X-100, and protease inhibitors (Halt Protease Inhibitor Cocktail Kit;
Pierce, Rockford, IL), 1 mMNa3VO4, 2 mMNaF, and 50mM phenyl-
methanesulfonylfluoride. Cells were scraped, and the lysates were
incubated in the buffer for 15 minutes on ice, and centrifuged for
20 minutes at 16,000g at 4°C. The supernatants were collected, and
protein concentration was determined by a modified Bradford method
(Bio-Rad Laboratories, Inc, Hercules, CA). For immunoblot analysis,
3× Laemmli sample buffer with 1 mM β-mercaptoethanol was added
to 40 μg of protein extract (35-200 μg) at a final concentration of
33%, and the samples were heated at 100°C for 5 minutes. Cell pro-
tein extracts were fractioned on a precast 7% NuPAGE TRIS-acetate
SDS gel (Invitrogen) followed by electrophoretic transfer to nitrocellu-
lose membranes (Pall Life Sciences, Ann Arbor, MI). The membranes
were incubated overnight (O/N) at 4°C with 0.2% Tween-20 in TBS
and 2% bovine serum albumin with rabbit monoclonal and polyclonal
antibodies. The blots were incubated with secondary antirabbit IgG
horseradish peroxidase–linked antibody in 0.2% Tween-20 in TBS
and 2% nonfat milk for 1 hour at room temperature (Cell Signaling).
The custom phosphoCaR antibody was used at a 1:75 dilution. Immu-
noreactive bands were detected using a combination product that de-
tects both chemiluminescence and fluorescence (Amersham ECL Plus
Western Blot Detection Reagents, GE Healthcare Bio-Sciences).
Immunohistochemistry
Formalin-fixed paraffin-embedded tumor sections were placed on
SuperFrost/Plus slides, deparaffinized in xylene, and rehydrated in an
ethanol gradient. For PTHrP, a goat polyclonal anti–human PTHrP-
(1-34) (sc-9680; Santa Cruz Biotechnology, Santa Cruz, CA) was used
at a 1:50 dilution, and the secondary antibody was biotinylated rabbit
anti-goat IgG (Vector Laboratories, Burlingame, CA) at a 1:200 dilu-
tion. For CaR, the custom phosphoCaR antibody was used at a 1:100
dilution, and the secondary antibody was biotinylated goat anti-rabbit
used at 1:200 (Vector Laboratories). The specificity of the secondary
antibodies was confirmed by the substitution of primary antibody with
an irrelevant rabbit IgG1 or goat IgG1, by omission of the primary
antibody and by the use of blocking peptide for PTHrP (sc-9680P;
Santa Cruz Biotechnology). Healthy adult human lung served as a pos-
itive control for phosphoCaR and PTHrP. A range of primary anti-
body dilutions were evaluated for phosphoCaR because this
antibody had not been validated for immunohistochemistry.
Signaling Pathway Analysis
For the analysis of MAPK phosphorylation, a human Proteome
Profiler antibody array was used according to the manufacturer’s in-
structions (R&D Systems, Minneapolis, MN). The human phospho-
MAPK antibody array is a nitrocellulose membrane with 21 different
antikinase antibodies (Abs), including three positive controls and six
negative controls, which are in duplicate. Positive controls are phos-
phorylated proteins, which are recognized by the antikinase Abs.
BEN and HARA lung SCC lines and their respective shRNA-CaR
SCC lines were seeded in duplicate at a density of 3 × 106 cells/
100-mm polystyrene tissue culture dish (Falcon, BD Biosciences)
in 10 ml of normal growth medium. After 24 hours, cells were
washed twice with DPBS and the culture medium was replaced with
10 ml of a sodium pyruvate and calcium chloride–free high-glucose
DMEM (Invitrogen) supplemented with 10% dialyzed triple 0.1-μm
sterile-filtered FBS (HyClone) and 4 mM L-glutamine alone (0.15 mM)
or supplemented with CaCl2 to a final concentration of 3.0 mM for
30 minutes. Total protein from whole cells was harvested using Nonidet
P-40 lysis buffer. Cell lysates were gently rocked for 30 minutes at 4°C
and then centrifuged at 14,000g for 5 minutes (4°C). The supernatants
were collected, and protein concentration was measured by the modi-
fied Bradford method (Bio-Rad Laboratories). A total of 300 μg of
protein were used for each array. Arrays were developed by chemilumi-
nescence (Amersham ECL Plus Western Blot Detection Reagents).
The array immunoreactivity was quantified using Typhoon 9410 and
ImageQuant TL Array Analysis software version 7 (GE Healthcare,
Piscataway, NJ).
DNA Extraction
DNA from all lung SCCs and HEK293T cells was prepared using
the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. General PCR conditions used to am-
plify CaR were an initial denaturation at 95°C for 2 minutes, 32 cycles
of denaturation at 97°C for 30 seconds, annealing at 65°C for 60 sec-
onds, and extension at 72°C for 1:30 minutes followed by elongation at
72°C for 7 minutes and termination at 4°C. All amplifications used a
high-fidelity polymerase (Platinum Taq HiFi Polymerase; Invitrogen).
Primers are listed in Table W2.
Extraction of DNA from Nonaffected and Lung SCC Tissue
for Sequencing
Each patient had two lung biospecimens, one with nonaffected
tissue (NAT) and the other an AJCC-staged lung SCC as determined
by a board-certified pathologist. None of the patients had received
chemotherapy or radiation therapy before acquisition of the tissue
samples. For the analysis of mutations or SNPs in CaR, patients’
tissues (SCC and the corresponding NAT for each patient) were
pulverized with a mortar and pestle in liquid nitrogen, put in an
Eppendorf tube with 180 μl of buffer ATL supplemented with 20 μl
of proteinase K, placed in a thermomixer, and incubated at 56°C O/N.
DNA was extracted and purified per manufacturer’s instructions using
the DNeasy Blood and Tissue Kit (Qiagen).
Sequencing
Standard PCR was used to generate high-fidelity Taq polymerase-
amplified PCR products and subsequent sequencing. Amplicons
were resolved on a 1% agarose gel to visualize the products. Each exon
product was sequenced using BigDye Terminator Cycle Sequencing
chemistry (Applied Biosystems). Sequencing reactions were run on
an Applied Biosystems 3730 DNA Analyzer automated sequencer.
Sequence Alignment
The alignmentwasmade using theClustalWprocedure inDNASTAR
Software v MegAlign 5.06 (Madison, WI).
Plasmids and Site-Directed Mutagenesis for Generation of
RWGT2 SNP Cell Lines
A construct containing the complete human CaR open reading
frame (ORF) cloned into pCMV6-XL4 was purchased from OriGene
Technologies, Inc, Rockville, MD (True Clone cat. no. SC119946;
ref. ID: NM_000388). For site-directed mutagenesis, the CaR ORF
was mutated using a strategy described previously [29] that involves
PCR amplification of the entire pCMV6-XL4-CaR cDNA plasmid
using the Expand Long Template PCR System (Roche, Indianapolis,
IN). The oligonucleotides that contained the desired mutations were
custom-synthesized, and these are listed in Table W1. A PCR product
of appropriate size (∼8.5 kb) was obtained for each mutation. The
PCR products were blunt-ended with T4 DNA polymerase (New
England Biolabs, Ipswich, MA), phosphorylated with T4 polynucleo-
tide kinase (New England Biolabs), circularized with T4 DNA ligase
(New England Biolabs), and transformed into DH5α cells. Once
clones containing the desired mutations were obtained and confirmed
by DNA sequencing, subregions of the mutated CaR ORFs were sub-
cloned back into the pCMV6-XL4-CaR cDNA parent plasmid to re-
move any unwanted mutations elsewhere in the plasmid that may have
been caused by Taq DNA polymerase errors. The complete wild-type
and mutated CaR ORFs were then subcloned as 3571-nucleotide
PshAI-NotI fragments into the SwaI-NotI sites of the GFP-expressing
lentiviral vector pCDH-CMV-MCS-EF1-copGFP (SystemBiosciences,
Mountain View, CA). Finally, a fusion protein between the wild-type/
mutant CaR ORFs and GFP was genetically engineered by replacing
the CaR stop codon with a NotI restriction site. This modified CaR
3′-end was cloned into the lentiviral vectors as a 517-nucleotide Bam-
HI-NotI fragment replacing the 751-nucleotide BamHI-NotI frag-
ment containing the wild-type CaR 3′-end. The entire CaR ORFs of
the final lentiviral vectors were confirmed by DNA sequencing. Gen-
eration of wild-type and variant CaR expression vectors was initiated
by cloning constructs into the pCDH-EF1-MCS-T2A-copGFP re-
porter vector (Systems Biosciences). pCDH cDNA CaR wild-type
and mutant constructs were subsequently packaged into VSV-G pseu-
dotyped lentiviral particle supernatant (Cincinnati Children’s Hospital
Medical Center Viral Vector Core, Cincinnati,OH). BENandRWGT2
cells were seeded at a density of 5 × 105 cells/6-mm well and incubated
O/N at 37°C. Twenty-four hours later, viral supernatant of each mutant
and wild-type construct with a MOI of 5, polybrene 8 μg/ml, and
DMEM + 10% FBS were added to each well to a total volume of
2 ml. Spinoculation was performed at 32°C for 1 hour at 2700 rpm.
Transduced cells expressed visible GFP within 48 hours and were
selected by FACS analysis.
Table W1. Human-Specific Primers for CaR.
Primer Set Forward Reverse
Human-specific primers used for calcium-sensing receptor PCR amplification of exon gDNA
CaR Exon 2 5′-AGTCTGCCACCCCTAGGCCC-3′ 5′-TGCGTTTGGTGCAGCTTTTCTCCA-3′
CaR Exon 3 5′-ACAGAGCATGCCATGAAGCCAGAG-3′ 5′-GCACCCCCAAGCCTGCTTCT-3′
CaR Exon 4 5′-GCCACCTCCACAACAGCCTGG-3′ 5′-TGGAGTTGCAGCCCAACTCTGC-3′
CaR Exon 5 5′-TGTGCAGGGCACAGCCTACCT-3′ 5′-TGTGCAGGGCACAGCCTACCT-3′
CaR Exon 7A 5′-CCCACCACCACATGTACACTCACA-3′ 5′-GCACGCCAGCAAGCCAAAGC-3′
CaR Exon 7B 5′-GCTTTGGCTTGCTGGCGTGC-3′ 5′-TCAGAGGAAAGGAGTCTGGGGCG-3′




Human-specific primers used for the amplification of the 481-bp calcium-sensing receptor PCR product
CaR 5′-CGGGGTACCTTAAGCACCTACGGCATCTAA-3′ 5′-GCTCTAGAGTTAACGCGATCCCAAAGGGCTC-3′
Human-specific primers used for the amplification of the 176-bp GAPDH PCR product
GAPDH 5′-TGCACCACCAACTGCTTAG-3′ 5′-GAGGCAGGGATGATGTTC-3′
Table W2. (A) Cell Line SNPs and (B) Human Nonaffected and Lung SCC Tissue SNPs.
(A)
Domain Cell Line Amino Acid Change Exon Codon Change Genotype Other
RWGT2 None
Cytoplasmic HEK293T A986S 7 GCC → UCC Heterozygous Polymorphism
HARA R990G 7 AGG → GGG Homozygous Polymorphism
BEN Q1011E 7 CAG → GAG Heterozygous Polymorphism
(B)
Domain Age, Sex, and Race* Amino Acid Change Exon Codon Change Genotype N † Tissue‡ Other
Cytoplasmic 69Y/M/Caucasian A986S 7 GCC → UCC Heterozygous 3 NAT and SCC Polymorphism
72Y/M/Caucasian
74Y/F/Caucasian
59Y/M/Caucasian R990G 7 AGG → GGG Heterozygous 1 NAT and SCC Polymorphism
68Y/F/Caucasian Q1011E 7 CAG → GAG Heterozygous 2 NAT and SCC Polymorphism
72Y/F/Black
*F indicates female; M, male; Y, years old.
†N , number of individuals affected with SNP from a total of 20 patients.
‡NAT indicates nonaffected pulmonary tissue; SCC, squamous cell carcinoma.
Figure W1. Extracellular calcium concentrations decreased cell viability in HEK293T cells but not lung SCCs. (A–D) MTT assays were
used to measure the cytotoxicity of Ca2+o and 2 mM spermine on HEK293T and lung SCC lines after 24 hours of treatment (*P < .05 vs
0.15 mM). There were no significant effects on cell viability of any of the lung SCCs (B–D); however, a dose-response decrease in cell
viability occurred in the HEK293T cells.
Figure W2. Escalating [Ca2+o] increased PTHrP mRNA levels of lung SCC lines as measured by quantitative real-time RT-PCR. (A–C)
Addition of 3.0 mM Ca2+ to lung SCC cultures for 2, 4, 8, and 24 hours resulted in significant increases in PTHrP/GAPDH mRNA ratios
compared with controls (0.15 mM) at all time points in all cell lines except BEN at 2 hours. The relative ratios of PTHrP mRNA to GAPDH
mRNA levels were expressed as mean ± SEM of three cultures per time point and concentration (*P < .05 vs 0.15 mM).
Figure W3. Immunohistochemistry detection of phosphoCaR and
PTHrP expression in tumors from HARA shRNA empty-vector and
HARA shRNA-CaR xenograft models of HHM. Immunohistochem-
istry for phosphoCaR is represented by panels on the right. PTHrP
immunohistochemistry is represented by panels on the left. HARA
shRNA empty-vector lung SCC (A–D). (A) Low-power magnification
revealing diffuse intense phosphoCaR staining of the nuclei and
cytoplasm of individual lung SCC cells, and nuclear staining of
the fibroblasts and endothelial cells of the tumor stroma. Magnifica-
tion, ×50. (B) Higher magnification of A, ×400. (C) Low-power
magnification showing marked diffuse granular PTHrP staining in
the cytoplasm with faint staining occasionally localized to the
nucleus in addition to the cytoplasm. Nuclei of fibroblasts in the
stroma demonstrate light PTHrP staining. Magnification, ×50. (D)
Higher magnification of C, ×400. HARA shRNA-CaR lung SCC
(E–H). (E) Low-power magnification of lung SCC revealing very light
phosphoCaR staining of the nuclei and minimal staining of the
cytoplasm (A vs E). Magnification, ×50. (F) Higher magnification
of E, ×400. (G) Low-power magnification showing decreased
PTHrP-positive staining of the cytoplasm and minimal staining of
the nuclei (G vs C). (H) Higher magnification of G, ×400. Normal adult
human lung tissue (I–L). (I) Low-power magnification of phosphoCaR
protein expression was located in the epithelium of the bronchus
and the smooth muscle of the pulmonary artery. Magnification,
×50. (J) Higher magnification showed phosphoCaR-positive staining
in the endothelial cells of the pulmonary venule and type 2 pneumo-
cytes. (K) PTHrP-positive staining was present in the endothelial cells
of pulmonary arteries. Magnification, ×50. Higher magnification de-
tected PTHrP staining in type 2 pneumocytes and in capillary and
venule endothelium, ×400.
Figure W4. Stimulation of CaR with 3.0 mM Ca2+ activated both ERK1/2 and JNK2 MAPK modules in the BEN and HARA lung SCC lines.
The human phospho-MAPK array was used to detect multiple phosphorylated kinases in human lung SCCs with either an intact CaR or a
silenced CaR after stimulation with Ca2+. BEN, BEN shRNA-CaR and HARA, HARA shRNA-CaR cells, 3 × 106 cells/100-mm plate were
seeded in duplicates and grown until ∼80% confluent. Twenty-four hours after seeding, growth medium was changed to 0.15 mM
calcium-free DMEM supplemented with 10% dialyzed FBS and L-glutamine for 4 hours. Cells were washed with DPBS, and medium
was changed to DMEM with 3.0 mM Ca2+, 10% dialyzed FBS, and L-glutamine for 30 minutes. Cells were harvested. Arrays were
incubated with 300 μg of cell lysate and were performed in duplicate. A and B depict the phosphorylation profile of BEN and HARA
lines as represented by normalized pixel volumes.
Figure W5. DNA sequence analysis CaR in lung SCC and HEK293T
cell lines and a schematic of the CaR demonstrating the locations
of SNPs and three PKC phosphorylation sites with known receptor
regulation. (A) DNA sequence analysis of CaR showing the nucle-
otide sequence of wild-type CaR on the left and the sequence with
the identified CaR SNP on the left. The corresponding amino acid
changes are represented below the changed nucleotide sequence.
(B) Topographical representation of the human CaR showing the
position of the identified SNPs in lung SCC and HEK293T cell lines.
Individual amino acids are represented by red circles; light blue
circles represent SNPs. Heterozygous or homozygous SNPs are de-
noted (het) and (hom), respectively. Dark blue circles represent PKC
phosphorylation sites known to regulate CaR activity. Pale orange
circles represent two additional putative PKC phosphorylation sites
with unknown activity.
